Help


from Wikipedia
« »  
All seven kinds of medications are modestly effective at decreasing the number of attacks in relapsing-remitting MS ( RRMS ) while the capacity of interferons and glatiramer acetate is more controversial.
Studies of their long-term effects are still lacking.
Comparisons between immunomodulators ( all but mitoxantrone ) show that the most effective is natalizumab, both in terms of relapse rate reduction and halting disability progression.
Mitoxantrone may be the most effective of them all ; however, it is generally not considered as a long-term therapy, as its use is limited by severe secondary effects.
The earliest clinical presentation of RRMS is the clinically isolated syndrome ( CIS ).
Treatment with interferons during an initial attack can decrease the chance that a person will develop clinical MS.

1.872 seconds.